Profound Medical Corp. filed its voluntary Form 10-Q with the SEC on November 5, 2026, covering the quarterly period ended September 30, 2026, reporting a net loss of $7,722 thousand and total revenue of $9,830 thousand for the third quarter.

Key Highlights

  • Total revenue of $9,830 thousand for Q3 2026, up from $5,289 thousand in Q3 2025, according to the filing.
  • Net loss of $7,722 thousand for the three months ended September 30, 2026, compared to $7,977 thousand in the prior-year period.
  • Nine-month net loss of $24,315 thousand for the period ended September 30, 2026, compared to $34,395 thousand for the same period in 2025.
  • Cash of $33,343 thousand as of September 30, 2026, down from $59,723 thousand at December 31, 2025.
  • Accumulated deficit of $312,055 thousand as of September 30, 2026, compared to $287,740 thousand at December 31, 2025.
  • 36,626,844 common shares outstanding as of November 5, 2026, up from 36,293,640 at December 31, 2025.
  • Basic and diluted net loss per common share of $0.21 for Q3 2026, compared to $0.26 in Q3 2025.

Profound Medical's Q3 2026 Revenue and Loss Position

According to the filing, Profound Medical Corp. (NASDAQ:PROF) reported total revenue of $9,830 thousand for the three months ended September 30, 2026, consisting of $4,106 thousand in recurring non-capital revenue and $5,724 thousand in capital equipment revenue. This compares to total revenue of $5,289 thousand in the same quarter of 2025, which included $4,066 thousand recurring and $1,223 thousand capital equipment. Gross profit for Q3 2026 was $7,680 thousand, against $3,931 thousand in Q3 2025.

The filing disclosed total operating expenses of $15,501 thousand for Q3 2026, comprising $5,806 thousand in research and development and $9,695 thousand in selling, general and administrative costs. The resulting operating loss was $7,821 thousand for the quarter. For the nine months ended September 30, 2026, total revenue was $17,650 thousand and total operating expenses were $40,367 thousand, producing an operating loss of $26,908 thousand, the company disclosed.

As of September 30, 2026, total assets were $58,154 thousand and total liabilities were $15,641 thousand, resulting in total shareholders' equity of $42,513 thousand, down from $66,434 thousand at December 31, 2025. The filing noted that long-term debt of $4,512 thousand is now classified within current liabilities at September 30, 2026, compared to $4,499 thousand in long-term liabilities at December 31, 2025. The company also noted that it voluntarily elected to file this quarterly report on Form 10-Q, as it qualifies as a Foreign Private Issuer and would otherwise be exempt from such filings.

What Was Disclosed

Profound Medical Corp. disclosed its unaudited condensed consolidated financial results for the quarter and nine months ended September 30, 2026, including revenue, operating losses, balance sheet position, cash balances, share count, and shareholders' equity movements.